SCHEMBL4946130

SCHEMBL4946130

Fc1ccccc1C1CCN(Cc2nc3cc(Cl)cc4c3n2CCC4)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 7/20 0.52
DRD3 P35462 4/20 0.52
DRD2 P14416 4/20 0.52
DRD4 P21917 3/20 0.39
CHRM4 P08173 1/20 0.38
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KCNH2 Q12809 2/20 0.36
NR1I2 O75469 1/20 0.35
ABCB11 O95342 1/20 0.35
LMNA P02545 1/20 0.35
ESR1 P03372 1/20 0.35
CYP1A2 P05177 1/20 0.35
PGR P06401 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4950360 0.89 GRM2 (0.41) GRM2DRD3DRD2DRD4KCNH2
SCHEMBL4947684 0.88 GRM2 (0.54) GRM2DRD3DRD2DRD4
SCHEMBL4947976 0.86 DRD2 (0.55) GRM2DRD2DRD4CHRM4
SCHEMBL4948946 0.84 DRD2 (0.44) GRM2DRD3DRD2DRD4HTR2A
SCHEMBL4947686 0.84 GRM2 (0.46) GRM2DRD3DRD2DRD4CHRM4
SCHEMBL4943868 0.83 DRD2 (0.51) GRM2DRD3DRD2DRD4KCNH2
SCHEMBL4950382 0.82 DRD2 (0.56) GRM2DRD3DRD2DRD4ALDH1A1
SCHEMBL4949187 0.80 DRD2 (0.46) GRM2DRD3DRD2DRD4ALDH1A1
SCHEMBL4947384 0.80 GRM2 (0.41) GRM2DRD3DRD2ALDH1A1
SCHEMBL4944033 0.80 GRM2 (0.51) GRM2DRD3DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US claimed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US claimed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
WO-2007018998-A2 TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators GRM2, GRM1, GRIN2B GRM2 1/4885DRD3 94/4885DRD2 51/4885
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators GRM2, GRM1, GRIN2B GRM2 1/4885DRD3 94/4885DRD2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.